The global cell and gene therapy market is growing rapidly, projected to expand fromUSD 37.14 billion in 2025toUSD 190.82 billion by 2033, driven by rising RD investment, increasing incidence of cancer and cardiovascular diseases, and a surge in clinical trials.
Thecell and gene therapy marketis witnessing transformative growth as advanced therapeutics reshape how we treat rare and life-threatening diseases. Valued atUSD 30.27 billion in 2024, the market is expected to soar at aCAGR of 22.7% from 2025 to 2033, reachingUSD 190.82 billion. With breakthroughs like CAR-T therapies gaining FDA approval and the number of clinical trials accelerating worldwide, this sector is quickly becoming a cornerstone of modern healthcare innovation.
Growth Drivers
Rising Pharmaceutical RD:Global pharmaceutical research and development investments are projected to reachUSD 232.5 billion by 2026, fueling more candidates in the cell and gene therapy pipeline.
Increasing Cancer and Cardiovascular Cases:With cancer and cardiovascular diseases ranking among the top global causes of death, demand for targeted cell and gene therapies is growing.
Expanding Clinical Trials:The number of active clinical trials rose by25% between 2019 and 2020, with over1,200 therapiescurrently in testing stages globally.
Market Challenges
Despite the potential, high operational expenses remain a hurdle. For instance, producing a single vial of 20 million cells can cost up toUSD 30,000, and overall gene therapy manufacturing may range fromUSD 500,000 to 1 million.
Opportunities Ahead
The surge in clinical research and global collaborations is creating opportunities for pharmaceutical companies, academic institutes, and contract manufacturing organizations to expand their footprint in this space.
Regional Insights
North America:Leading the market due to strong healthcare spending and institutional funding.
Europe:ReportedUSD 2.6 billionin CGT funding in 2020, a103% increasecompared to prior years.
Asia-Pacific Rest of World:Emerging as growing markets with expanding biotech infrastructure.
Segment Highlights
Therapy Type:Cell therapy dominates, with CAR-T leading in oncology treatments.
Delivery Method:Ex vivo delivery is the largest segment due to its precision and effectiveness.
End-User:Pharmaceutical and biotechnology companies are projected to post the highest growth.
Application:Oncology remains the largest application area, with rising demand in dermatology and musculoskeletal treatments.
Key Players
Thermo Fisher Scientific
Merck KGaA
Charles River Laboratories
Lonza
Catalent
WuXi AppTec
Takara Bio Inc.
Nikon Corporation
FUJIFILM Holdings Corporation
Hoffmann-La Roche Ltd.
Oxford Biomedica plc
Amgen Inc.
Novartis AG
Pfizer Inc.
Biogen Inc.
Recent Developments
Charles River Laboratoriesacquired Cognate BioServices to expand CGT manufacturing capabilities (2021).
Thermo Fisher Scientificpurchased Henogen S.A. forUSD 859.7 millionin 2021 and acquired Brammer Bio forUSD 1.7 billionin 2019, strengthening its position in viral vector manufacturing.
Conclusion
With a projected fivefold market growth by 2033, cell and gene therapy is set to revolutionize healthcare by providing personalized, effective, and potentially curative treatments. Companies that invest early in manufacturing capabilities and clinical trial pipelines are likely to lead this fast-evolving market.
About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us:
Email:sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website:https://straitsresearch.com/
